Your browser doesn't support javascript.
loading
Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis.
Takagi, Satoshi; Sasaki, Yuki; Koike, Sumie; Takemoto, Ai; Seto, Yosuke; Haraguchi, Mizuki; Ukaji, Takao; Kawaguchi, Tokuichi; Sugawara, Minoru; Saito, Masanori; Funauchi, Yuki; Ae, Keisuke; Matsumoto, Seiichi; Fujita, Naoya; Katayama, Ryohei.
Afiliación
  • Takagi S; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Sasaki Y; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Koike S; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Takemoto A; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Seto Y; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Haraguchi M; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Ukaji T; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Kawaguchi T; Project for Development of Genomics-based Cancer Medicine, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Sugawara M; Project for Development of Genomics-based Cancer Medicine, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Saito M; Department of Orthopedic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Funauchi Y; Department of Orthopedic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Ae K; Department of Orthopedic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Matsumoto S; Sarcoma Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Fujita N; Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Katayama R; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. ryohei.katayama@jfcr.or.jp.
Oncogene ; 40(36): 5548-5558, 2021 09.
Article en En | MEDLINE | ID: mdl-34302117
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Lisofosfolípidos / Osteosarcoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Oncogene Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Lisofosfolípidos / Osteosarcoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Oncogene Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Japón